Epigenomics (ECX.F) Stock Price
Epigenomics Price
Revenue at Epigenomics has contracted by 16.9% per year over the past 18 years to 339,200.00 EUR. For Epigenomics, the net margin of -1,315.9% is up versus -1,512.9% a few years ago.
Epigenomics stock price
Epigenomics business model & stock analysis
Frequently asked questions about Epigenomics
10 analysts currently rate the Epigenomics stock: 9 recommend buying, 1 holding and 0 selling.
The expected revenue of Epigenomics is 4.29 M EUR. This figure is based on current financial data and reflects the company's business performance.
The profit cannot currently be calculated for Epigenomics.
The P/E ratio cannot be calculated for Epigenomics at the moment.
The price-to-sales ratio (P/S) of Epigenomics is currently 0.18. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Epigenomics stock.
The Eulerpool Quality Score for Epigenomics is 2/10.
The ISIN of Epigenomics is DE000A37FT41. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Epigenomics is A3H218. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Epigenomics is ECX.F. The ticker symbol is used to trade Epigenomics shares on the stock exchange.
Epigenomics stock
Epigenomics Peer Group
All fundamentals and in-depth analysis of Epigenomics
Our stock analysis for Epigenomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Epigenomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.